(Q38849191)

7 September 2017

Clinical development of new drug-radiotherapy combinations (English)

1 reference

7 September 2017

4

1 reference

7 September 2017

David Sebag-Montefiore

35

David Sebag-Montefiore

0 references

Richard Baird

Richard D Baird

9

0 references

Richard Adams

Richard A Adams

8

0 references

Maria A. Hawkins

Maria A Hawkins

26

0 references

Lucinda J. Billingham

Lucinda Billingham

10

0 references

Emma Hall

Emma Hall

22

0 references

Ian Stratford

Ian J Stratford

38

0 references

Tim M. Illidge

Tim Illidge

27

0 references

author name string

Ricky A Sharma

1

1 reference

7 September 2017

Ruth Plummer

2

1 reference

7 September 2017

Julie K Stock

3

1 reference

7 September 2017

Ozlem Ataman

5

1 reference

7 September 2017

Stephen Kelly

6

1 reference

7 September 2017

Robert Clay

7

1 reference

7 September 2017

Sarah R Brown

11

1 reference

7 September 2017

Sean Buckland

12

1 reference

7 September 2017

Helen Bulbeck

13

1 reference

7 September 2017

Anthony J Chalmers

14

1 reference

7 September 2017

Glen Clack

15

1 reference

7 September 2017

Aaron N Cranston

16

1 reference

7 September 2017

Lars Damstrup

17

1 reference

7 September 2017

Roberta Ferraldeschi

18

1 reference

7 September 2017

Martin D Forster

19

1 reference

7 September 2017

Julian Golec

20

1 reference

7 September 2017

Russell M Hagan

21

1 reference

7 September 2017

Axel-R Hanauske

23

1 reference

7 September 2017

Kevin J Harrington

24

1 reference

7 September 2017

Tom Haswell

25

1 reference

7 September 2017

Hazel Jones

28

1 reference

7 September 2017

Andrew S Kennedy

29

1 reference

7 September 2017

Fiona McDonald

30

1 reference

7 September 2017

Thorsten Melcher

31

1 reference

7 September 2017

James P B O'Connor

32

1 reference

7 September 2017

John R Pollard

33

1 reference

7 September 2017

Mark P Saunders

34

1 reference

7 September 2017

Melanie Smitt

36

1 reference

7 September 2017

John Staffurth

37

1 reference

7 September 2017

Stephen R Wedge

39

1 reference

7 September 2017

NCRI CTRad Academia-Pharma Joint Working Group

40

1 reference

7 September 2017

language of work or name

English

0 references

publication date

1 June 2016

1 reference

full work available at URL

7 September 2017

http://eprints.whiterose.ac.uk/102226/

content deliverer

White Rose Research Online

object has role

published version

copyright license

Creative Commons Attribution 4.0 International

0 references

https://doi.org/10.1038/nrclinonc.2016.79

copyright license

Creative Commons Attribution 4.0 International

object has role

published version

0 references

published in

Nature Reviews Clinical Oncology

1 reference

7 September 2017

13

1 reference

7 September 2017

10

1 reference

7 September 2017

627-642

1 reference

Creative Commons Attribution 4.0 International

7 September 2017

start time

1 June 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

The Swedish Council on Technology Assessment in Health Care (SBU) Systematic Overview of Radiotherapy for Cancer including a Prospective Survey of Radiotherapy Practice in Sweden 2001--Summary and Conclusions

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Role of radiation therapy in palliative care of the patient with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Expanding global access to radiotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Stereotactic body radiotherapy for oligometastases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Surgery versus SABR for resectable non-small-cell lung cancer – Authors' reply

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Radiotherapy and cellular signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Repopulation of cancer cells during therapy: an important cause of treatment failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Bystander signalling: exploring clinical relevance through new approaches and new models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Bystander effects and radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Radiation and the microenvironment - tumorigenesis and therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Role of Local Radiation Therapy in Cancer Immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Turning Radiotherapy into an Effective Systemic Anti-cancer Treatment in Combination with Immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Radiotherapy and the tumor microenvironment: mutual influence and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Microenvironment and radiation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

The tumor-immune microenvironment and response to radiation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Combining radiation and cancer gene therapy: a potential marriage of physical and biological targeting?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Potential and limitations of bacterial-mediated cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

The concurrent chemoradiation paradigm--general principles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Patient-reported outcomes in the evaluation of toxicity of anticancer treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Drug combination studies and their synergy quantification using the Chou-Talalay method

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Quantitative methods for assessing drug synergism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Staged Risk Management of Candidate Drug Efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

A systematic methodology review of phase I radiation dose escalation trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Sequential designs for phase I clinical trials with late-onset toxicities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Dose escalation methods in phase I cancer clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Dose-finding based on efficacy-toxicity trade-offs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: a prospective population-based study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

New radiotherapy approaches in locally advanced non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Increasing the Therapeutic Ratio of Stereotactic Ablative Radiotherapy by Individualized Isotoxic Dose Prescription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

A product of independent beta probabilities dose escalation design for dual-agent phase I trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Randomized phase II trial designs with biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Effective incorporation of biomarkers into phase II trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Envisioning the future of early anticancer drug development.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Methods of joint evaluation of efficacy and toxicity in phase II clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Sharing Clinical Trial Data--A Proposal from the International Committee of Medical Journal Editors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Radiation therapy quality assurance in clinical trials--Global Harmonisation Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Patient-derived xenograft models: an emerging platform for translational cancer research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

The mighty mouse: genetically engineered mouse models in cancer drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Small animal radiotherapy research platforms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

A review of treatment planning for precision image-guided photon beam pre-clinical animal radiation studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Recovery and repopulation in mouse skin as a function of time after x-irradiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Radiosensitisation in normal tissues with oxygen, carbogen or nicotinamide: therapeutic gain comparisons for fractionated x-ray schedules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Skin sensitization by misonidazole: a demonstration of uniform mild hypoxia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

The Effect of Multiple Small Doses of X Rays on Skin Reactions in the Mouse and a Basic Interpretation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Consequential late effects in normal tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Early and late radiation reactions in mouse feet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Role of type II pneumocyte senescence in radiation-induced lung fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Murine models of pulmonary fibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Radiation induced lung injury: prediction, assessment and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Molecular mechanisms and treatment of radiation-induced lung fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Differential effects of cyclosporin and etanercept treatment on various pathologic parameters in a murine model of irradiation-induced mucositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Tumor vascular changes mediated by inhibition of oncogenic signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

High-resolution in vivo imaging of fluorescent proteins using window chamber models.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Research activity and the association with mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Radioprotection of normal tissue cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Immunologic correlates of the abscopal effect in a patient with melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Combinations of immunotherapy and radiation in cancer therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Early Proctoscopy is a Surrogate Endpoint of Late Rectal Toxicity in Prostate Cancer Treated With Radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Transforming growth factor β-1 (TGF-β1) is a serum biomarker of radiation induced fibrosis in patients treated with intracavitary accelerated partial breast irradiation: preliminary results of a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

The association between TGF-β1 polymorphisms and radiation pneumonia in lung cancer patients treated with definitive radiotherapy: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Radiobiological considerations in the design of clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

The hallmarks of cancer and the radiation oncologist: updating the 5Rs of radiobiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

The population benefit of radiotherapy for cervical cancer: Local control and survival estimates for optimally utilized radiotherapy and chemoradiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Longitudinal changes in tumor perfusion pattern during the radiation therapy course and its clinical impact in cervical cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Survival in cervix cancer patients treated with radiotherapy followed by radical surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Posttreatment cut-off levels of squamous cell carcinoma antigen as a prognostic factor in patients with locally advanced cervical cancer treated with radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Radiotherapy for bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Quality of Life Outcomes for Bladder Cancer Patients Undergoing Bladder Preservation with Radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Magnetic Resonance Imaging–Detected Tumor Response for Locally Advanced Rectal Cancer Predicts Survival Outcomes: MERCURY Experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

End points in anal cancer: hopes for a common language.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT: does it have a place in predicting survival in patients with glioblastoma multiforme?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.79

Pattern of failures and clinical outcome of patients with locally advanced cervical cancer treated with a tailored integrated therapeutic approach.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27245279

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Tolerance of normal tissue to therapeutic irradiation

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27245279

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2016.79

1 reference

10.1038/NRCLINONC.2016.79

7 September 2017

0 references

CORE ID

185500759

0 references

Dimensions Publication ID

0 references

1 reference